Bristol Myers Squibb shares slide 3.25%

Bristol-Myers Squibb shares fell 3.25% on 8 September to finish trading at $64.69. GuruFocus separately reported a 3.2% single-day decline for the session.

The retreat outpaced broader sector weakness, as the Pharmaceuticals and Medical Research sector dropped 2.65%. Competitors also saw losses, with Johnson & Johnson slipping 1.84% and Eli Lilly sliding 2.24%, while Amgen tumbled 8.94%.

The drop occurred alongside the company's announcement of positive topline results from its registrational Phase 2 QUINTESSENTIAL trial. That study evaluates arlocabtagene autoleucel, an investigational GPRC5D-directed CAR T cell therapy.

Despite the daily decline, Bristol-Myers Squibb stock maintained a 24.0% gain year to date through the session close. Over the trailing twelve months, the stock remained up 45.1%, trading between a 52-week low of $42.52 and a 52-week high of $68.64.